Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 19/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pumaprazole SCHEMBL29493303 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1812546 | 0.93 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1812877 | 0.91 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1817519 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1812857 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL9099268 | 0.90 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL9097344 | 0.89 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1816283 | 0.89 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7503350 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL6381033 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111249250-A | Oral capsule for treating helicobacter pylori infection | 上海理工大学 | 2020-06-09 | — | — | CN | claimed |
| US-10130618-B2 | Pharmaceutical combinations of dabigatran and proton pump inhibitors | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2018-11-20 | — | — | US | claimed |
| US-20170035745-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2017-02-09 | — | — | US | claimed |
| EP-2933002-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-10-21 | — | — | EP | claimed |
| WO-2015155281-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-10-15 | — | — | WO | claimed |
| WO-2015155307-A1 | PHARMACEUTICAL COMBINATIONS OF RIVAROXABAN AND PROTON PUMP INHIBITORS | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-10-15 | — | — | WO | claimed |
| EP-2929885-A1 | PHARMACEUTICAL COMBINATIONS OF RIVAROXABAN AND PROTON PUMP INHIBITORS | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-10-14 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | claimed |
| US-20130078305-A1 | Pharmaceutical Compositions For The Coordinated Delivery Of NSAIDs | POZEN, INC. (US) | 2013-03-28 | — | — | US | claimed |
| CN-1147292-C | Double capsule for the administration of active principles in multiple therepies | ������ҩ������˾ | 2004-04-28 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0841904-B1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | ALTANA PHARMA AG (DE) | 2003-02-05 | — | — | EP | claimed |
| US-6132768-A | FOR TREATING DISORDERS CAUSED BY HELICOBACTER | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-17 | — | — | US | claimed |
| EP-0683780-B1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEM FAB (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0841904-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-05-20 | — | — | EP | claimed |
| US-5665730-A | GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-09 | — | — | US | claimed |
| WO-1997002021-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-01-23 | — | — | WO | claimed |
| EP-0683780-A1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1995-11-29 | — | — | EP | claimed |
| WO-1994018199-A1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-08-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035745-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS | ABCB11, SLC9A5, SLC9A3 | CYP3A4 70/4885CYP2C9 20/4885CYP2D6 18/4885 |
| US-10130618-B2 | Pharmaceutical combinations of dabigatran and proton pump inhibitors | ABCB11, SLC9A5, SLC9A3 | CYP3A4 70/4885CYP2C9 20/4885CYP2D6 18/4885 |
| US-20150086497-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | CYP3A4 2827/4885CYP2C9 2552/4885CYP2D6 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.